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Abstract
Introduction—As international travel increases, travellers may be at increased risk of acquiring 
infectious diseases not endemic in their home countries. Many journal articles and reference books 
related to travel medicine cite that between 22–64% of international travellers become ill during or 
after travel; however, this information is minimal, outdated and limited by poor generalizability. 
We aim to provide a current and more accurate estimate of the proportion of international 
travellers who acquire a travel-related illness.
Methods—We identified studies via PubMed or travel medicine experts, published between 
January 1, 1976–December 31, 2016 that included the number of international travellers acquiring 
a travel-related illness. We excluded studies that focused on a single disease or did not determine a 
rate based on the total number of travellers. We abstracted information on traveller demographics, 
trip specifics, study enrollment and follow-up and number of ill travellers and their illnesses.
Results—Of 743 studies, nine met the inclusion criteria. The data sources were from North 
America (four studies) and Europe (five studies). Most travellers were tourists, the most frequent 
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destination regions were Asia and Africa, and the median trip duration ranged from 8–21 days. Six 
studies enrolled participants at the travellers’ pre-travel consultation. All studies collected data 
through either extraction from the medical record, weekly diaries, or pre- and post-travel 
questionnaires. Data collection timeframes varied by study. Between 6–87% of travellers became 
ill across all studies. Four studies provided the best estimate: between 43–79% of travellers who 
frequently visited developing nations (e.g. India, Tanzania, and Kenya) became ill; travellers most 
frequently reported diarrhoea.
Conclusion—This is the most comprehensive assessment available on the proportion of 
international travellers that develop a travel-related illness. Additional cohort studies would 
provide needed data to more precisely determine the rates of illness in international travellers.
Keywords
International travel; travel; illness
Introduction
Projections suggest the annual number of international travellers will reach 1.8 billion by 
2030. Europe remained the most common destination for international travellers in 2015, 
accommodating approximately 600 million arrivals, an increase of almost 5% from the 
previous year. However, travellers are increasingly visiting regions with emerging 
economies, and travel to Asia, Africa, Latin America and the Middle East is projected to rise 
in the coming years.1 Of the top 10 international destinations in 2015 identified by the 
United Nations World Tourism Organization, four (China, Turkey, Mexico and the Russian 
Federation) were outside of the United States and Western Europe; combined, these four 
destinations accounted for 160 million arrivals.1
As international travel increases and travel destinations diversify, travellers increasingly 
acquire infectious diseases not endemic in their home countries2; therefore, there is a need 
for current and accurate data on the proportion of international travellers who acquire an 
illness while abroad. Despite this need, estimating this proportion is difficult, since ill 
travellers may not seek care from a healthcare provider if they have mild symptoms or do 
not know where or how to access care in the country they are visiting. Also, travellers may 
not attribute their illness to travel, especially if they acquire illnesses with long incubation 
periods and their symptoms manifest weeks or months after returning home.
Global, clinician-based surveillance of travel-related illness is one way to address this need, 
and is a primary objective of travel and tropical medicine surveillance networks such as 
GeoSentinel.2–4 Although such data are useful, there are limits to their application, 
especially when determining the rates of an illness globally or for a specific geographic area. 
For example, a GeoSentinel analysis on the surveillance of ill returned travellers from 2007–
11 reported that 34% of illnesses reported to GeoSentinel were gastrointestinal,3 but readers 
must interpret this estimate with caution, since GeoSentinel data come from a finite number 
of travel and tropical medicine clinics and, more importantly, do not capture total traveller 
numbers. Without this denominator, the rate of illness or incidence cannot be determined.3,5
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Estimating the proportion of international travellers who acquire a travel-related illness is 
important for two main reasons. First, the current trend toward increased globalization and 
urbanization will likely affect the prevalence and epidemiology of travel-related disease; 
knowing the proportion of travellers that become ill can be useful in observing trends over 
time. Second, medical providers can use this estimate to help provide optimal pre-travel 
advice to their patients. Many travel medicine journal articles and reference books currently 
cite an illness estimate of 22–64%5,6; however, the basis for this estimate includes 
information that is based upon a limited number of studies, is outdated, and involves only 
specific traveller populations and, thus, is limited by poor generalizability. To address this 
knowledge gap, we conducted a literature search and review in an effort to provide a current 
and accurate estimate of the number of travellers that acquire travel-related illnesses during 
or after international travel.
Materials and Methods
Study Identification and Selection
We searched PubMed for relevant English-language studies, with specified search 
algorithms (international travel or traveller[s] and infectious disease[s]), published between 
1 January 1976 and 31 December 2016 (>40 years). Our search included clinical studies, 
clinical trials, journal articles, meta-analyses, observational studies, reviews and systematic 
reviews. We interviewed experts in the field of travel medicine, identified through 
publications and field notoriety, to identify additional studies.
We selected studies if they described the number of travellers with travel-related illness 
either during or after international travel. From this initial selection, we excluded studies that 
focused on a single disease or that did not include the total number of travellers (a 
denominator to determine a rate) in addition to the total number ill.
Data Extraction and Analysis
We abstracted and summarized the following variables from the studies: baseline traveller 
demographics, trip specifics (including travel reason, duration and destination), total number 
of travellers, number of ill travellers, illnesses acquired, the data source, enrollment 
information and the type(s) and frequency of administration of the data collection 
instrument(s). We critically evaluated each study based on these characteristics to determine 
the best estimate of the number of international travellers with a travel-related illness.
Narrative Review Methodology
Differences in study design, purpose, objectives and outcomes resulted in a large 
heterogeneity of articles. We performed a narrative review on the available evidence for our 
clinical question and qualitatively described the findings of the included studies.
Results
We identified 743 studies through the literature search and consultation with experts; nine 
met the inclusion criteria. Publication dates ranged from 1985–2016, and the data sources 
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were from North America (four studies) and Europe (five studies) (Table 1). The number of 
study participants ranged from 122 (Balaban et al.) to 10 555 (Steffen) travellers. All 
travellers were adults 18 years or older; the median age of travellers ranged from 35 years 
(Vilkman et al.) to 52 years (Stoney et al.). Travellers were predominantly female in six of 
the nine studies. Among studies with information available, most travellers were travelling 
for tourism or vacation, the most frequent destination regions were Asia and Africa, and the 
median trip duration ranged from 8 days (Dia et al.) to 21 days (Steffen). Travel was to both 
developed (e.g. Canada and Italy) and developing (e.g. Tanzania and Nepal) countries.
Enrollment of Study Participants
The studies recruited and enrolled travellers through various mechanisms (Table 2). Six 
studies enrolled participants at the travellers’ pre-travel consultation with a healthcare 
provider, two studies enrolled participants during travel to or from their destination, and one 
study enrolled participants through random-digit-dialing. All studies collected data through 
extraction from medical records, weekly diaries, or pre- and post-travel questionnaires; data 
collection timeframes varied by study.
Proportion Ill
Across all studies, 6–87% of travellers became ill during or after travel (Table 1). In four of 
the nine studies, less than half of travellers became ill during or after travel; travellers were 
predominantly tourists in three of the four studies (71% tourists in Stoney et al.; 100% 
tourists in Rack et al.; and 93% tourists in Steffen et al.). In the fourth study (Balaban et al.), 
the majority of travellers provided scientific or technical assistance, performed teachings or 
trainings and/or attended a professional meeting. In these studies, travel destinations 
included both developed and developing nations. In the remaining five studies, 64–87% of 
travellers became ill during or after travel; these travellers were also predominantly tourists. 
Among these remaining studies, travellers frequently travelled to developing nations; three 
of these studies included information on the top five destination countries: India, Tanzania 
and Kenya were among the top five travel destinations for all three studies, and Thailand was 
among the top five travel destinations for two studies.
Types of Illness
In seven studies for which information was available on the type of illness acquired while 
abroad (Stoney et al. did not include this information), travellers were most frequently ill 
with diarrohea (Table 3). Travellers also frequently reported gastrointestinal symptoms in 
addition to diarrhoea, such as nausea, vomiting, constipation, or abdominal cramps. In Dia et 
al., travellers most often reported a dermatological condition (75%). Other symptoms 
reported with moderate frequency included respiratory tract symptoms, skin problems, and 
fever. Between 8– 55% of ill travellers sought medical care during travel or after travel 
within the studies’ follow-up period. The follow-up period post-travel among the studies 
varied. The shortest period of post-travel follow-up was in Steffen, in which a questionnaire 
was administered on the flight back to Switzerland, and the longest period of post-travel 
follow-up was in Stoney et al. in which travellers were asked about travel anytime in the 
previous 12 months. Other follow-up periods ranged from a week after return (Dia et al.), to 
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seven months after departure (Steffen et al.); two studies did not provide follow-up periods. 
Between <1–3% of travellers were hospitalized.
Discussion
Two studies (Hill in 2000 and Steffen et al. in 1987)7,8 are commonly cited in the travel 
medicine literature when discussing the proportion of international travellers who become ill 
with a travel-related illness while abroad. Despite the large number of travellers in these two 
studies and the exposures in various geographic regions, these estimates may not be 
representative of all international travellers, even though considered the best estimates 
available. These two studies are dated, lacking diversity in the type of travel (e.g. tourists or 
conference attendees) and nationality of travellers included. During the past 40 years, seven 
additional studies,9–15 six of which were published since 2006, have provided information 
that may lead to a more generalizable and accurate estimate of the proportion of 
international travellers that acquire a travel-related illness.
Among the nine studies assessed, the majority (six studies) prospectively enrolled travellers 
during their pre-travel consultation with a healthcare provider.7,9,10,12,13,15 Travellers who 
attend a pre-travel consultation receive education on mitigation of health risks during travel 
and prevention of infectious diseases, including personal protective measures, 
chemoprophylaxis, and vaccination.16 Attendance at a pre-travel consultation may result in 
decreased illness if clinicians provide travellers with prevention information17 and the 
travellers adhere to these preventive measures. Additionally, travellers who attend a pre-
travel consultation may also have greater motivation to prevent illness than those who do not 
attend. Therefore, the studies that enrolled travellers at the pre-travel consultation may not 
portray an accurate estimate of travel-related illness for all travellers because the travellers 
underwent pre-travel health preparations. On the other hand, enrollment of travellers who 
attend pre-travel consultations may overestimate the proportion of travel-related illness due 
to overrepresentation of travellers visiting developing regions (due to the need for 
vaccinations and chemoprophylaxis). This latter hypothesis is supported by findings in 
Vilkman et al.: travellers were enrolled at the pre-travel consultation, and 84% visited Asia 
or Africa, while only 3% visited North America or Europe; almost 80% of travellers became 
ill while abroad.13 In addition, in the United States, many health insurance plans do not pay 
for pre-travel health consultations and vaccines, which may result in a selection bias among 
the studies that enrolled travellers at the pre-travel consultation since they likely included 
only travellers with the means to pay out-of-pocket for their preventive care. In Europe, a 
similar bias may arise due to country variation on whether pre-travel consultation is 
provided by the public or the private sector.
The studies also included varied completion rates for the data collection instruments, 
possibly creating a reporting bias. For example, Chen et al. found that white and older 
travellers had a higher completion rate of the data collection instrument than other 
ethnicities and younger travellers,10 likely decreasing representativeness. Balaban et al. had 
the poorest follow-up of all studies, in which only 14% of respondents completed the pre-
travel survey and only 7% completed both surveys.9 In addition, the follow-up periods for 
data collection varied among studies, from as short as during the flight home14 to up to 12 
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months after departure11; two studies did not mention the timeframe of the follow-up period.
9,12
 Long follow-up periods may increase recall bias, resulting in an underestimation of 
travel-related illness if the traveller was unable to recall feeling ill, or an overestimation of 
travel-related illness if they became ill months after returning home but attributed their 
symptoms to travel. On the contrary, short follow-up periods may not capture illness from 
diseases with long incubation periods, such as Plasmodium ovale or Plasmodium vivax 
malaria. Exclusion of travellers from the study for travel lasting longer than 2 or 3 
months12,14,15 may create similar issues.
Differences in the main objectives of each study’s surveys or questionnaires may also 
introduce bias. For example, in Dia et al., 87% of travellers, the most of any study, 
experienced health a travel-related complaint.15 The post-travel questionnaire in this study 
included specific questions about arthropod bites and sunburns, which likely contributed to 
the high prevalence of dermatological complaints in this cohort. In five other studies,
7,8,10,12,14
 travellers were asked about ‘skin problems’, ‘dermatosis’ or ‘dermatological 
problems’, while only Vilkman et al. further specified the exclusion of dry skin, atopy, acne 
and insect stings, while including sunburn, sun rash and infected skin due to insect stings as 
travel-related illnesses. The inclusion or exclusion of exposures or illnesses in the 
questionnaires or during data analysis may create variability in the proportion of ill travellers 
reported among studies.
The variation in travel reasons and traveller age may also affect the generalizability of the 
estimates from these studies. Although the majority of travellers were tourists, there were 
travellers with other travel reasons enrolled; these variations in travel reason may affect the 
generalizability of results. Chen et al. found higher proportions of business travellers and 
volunteers/missionaries/aid workers,10 while Stoney et al. included the largest proportion of 
travellers visiting friends and relatives (VFR) (18%)11 and Balaban et al. included only 
travellers from a large American public health agency.9 Each travel group has different 
characteristics that may place them at either increased or decreased risk of acquiring an 
illness while abroad. For example, VFR’s may be prone to acquiring preventable infectious 
diseases while abroad due to lack of risk awareness, travel to high-risk destinations, cultural 
or financial barriers that preclude access to pre-travel care, and approximating the living 
conditions of the local community.18,19 Even VFRs that do receive pre-travel care may 
encounter financial barriers preventing them from filling prescriptions for prophylactic 
medications or receiving certain vaccines, or may face cultural barriers that could decrease 
their adherence to recommendations while abroad. American public health agency workers, 
despite most travelling to Africa or Asia, may be at lower risk of travel-related illness due to 
prior knowledge of travel-related risks; they may also be more proactive about taking 
preventive measures and travel preparations than tourists or VFRs, and receive pre-travel 
care free of charge. The median traveller age may also affect generalizability; travellers in 
Stoney et al. had the highest median age among the nine studies, likely due to the 
administration of the questionnaire through random-digit-dialing of landline phone numbers.
11
Destination, in addition to duration and season of travel, also contributes to the likelihood of 
acquiring a travel-related illness.20 Dia et al. only included French travellers visiting 
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Senegal, predominantly during the dry season,15 which limits the generalizability of this 
study’s data to both the other countries as well as Senegal’s wet season. India, Tanzania and 
Kenya were among the top five travel destinations for the four studies where more than half 
of travellers became ill. Travel to the Indian subcontinent more than doubled the risk of 
becoming ill relative to other included destinations,7,12 and India was the most common 
country of travel among travellers who reported a health problem.10 India has a number of 
infectious disease risks for travellers, including malaria, dengue, chikungunya, hepatitis and 
tuberculosis.21 Travel to India accounts for almost 60% of typhoid fever among international 
travellers returning to the United States,22 and the highest worldwide burden of rabies, 
resulting in high numbers of individuals, including travellers, who may need post-exposure 
prophylaxis.21 Outbreaks may also affect the number of travellers that become ill while 
abroad; for example, the H1N1 pandemic in 2011 possibly contributed to illness among 
travellers.10
Two studies include data collected in the 1980s,8,14 one of which is included in the currently 
cited estimate.8 Although these studies provide the largest total number of international 
travellers, travel has changed dramatically over the past 40 years. Increased air travel and 
access to developing countries places travellers at higher risk of encountering infectious 
diseases not endemic in their home countries, such as malaria or other vector-borne diseases.
23
 In addition, chemoprophylaxis for malaria has evolved significantly since the 1980s with 
the introduction of mefloquine in 1989, doxycycline in 1992 and fixed-dose atovaquone-
proguanil in 2000.24 New vaccines and updates to travel vaccine recommendations25 likely 
also affect the proportion of international travellers that acquire a travel-related illness. 
Similarly, certain destination-specific illness risks have changed over the past 40 years. For 
example, the risk of acquiring an illness such as malaria, where national and global control 
programs successfully decreased disease prevalence, declined substantially,26 while the risk 
of acquiring other emerging infectious diseases, such as Zika virus,27 has simultaneously 
increased.
Despite the limitations and biases of the nine studies included in this analysis, four of these 
studies provide improved estimates on the number of travellers that acquire a travel-related 
illness.7,10,12,13 These four studies included data abstraction at the pre-travel consultation to 
obtain baseline characteristics, administered at least one post-travel questionnaire, enrolled 
travellers going to a variety of destinations and included data from the last 20 years to reflect 
recent rises in international travel. In these four studies, between 43–79% of travellers 
reported developing a travel-related illness; these were predominantly tourists from the 
United States and Europe that attended a pre-travel consultation and became ill during or 
after travel to Asia or Africa (more specifically, India, Tanzania, or Kenya). However, this 
estimate is limited to specific populations of travellers, and is subject to the biases of the 
included studies previously described. The other five studies8,9,11,14,15 provided estimates 
for very specific groups of travellers (e.g. public health workers, travellers to Senegal) or 
were outdated.
The most common infectious disease illnesses acquired abroad are usually 
gastrointestinal5,6; our findings support this. From seven studies among eight with available 
information, diarrhoea was the most frequent illness reported; however, the proportion of 
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travellers with diarrhoea varied considerably among the studies, and we cannot draw 
conclusions on travellers’ diarrhoea risk. Additionally, the numbers of travellers that sought 
medical care or were hospitalized must be interpreted with caution; it is unknown if medical 
care was sought for an infectious disease acquired during travel or for exacerbations of 
chronic conditions or non-travel-related illnesses or complaints.
A limitation of this narrative review is that only one database (PubMed) was searched and 
only English articles were included; thus, publications from Europe or other regions may 
have been missed. However, this is the most comprehensive assessment available on the 
proportion of international travellers that develop a travel-related illness. Epidemiologists 
may use this estimate to observe trends in travel-related illness, and clinicians may use the 
results to provide optimal pre-travel advice to their patients. Researchers may further 
delineate the proportion of international travellers that acquire a travel-related illness by age, 
travel reason, destination and duration of travel.
The best method to determine the proportion of travellers that become ill during or after 
travelwould be to perform a prospective, multi-national study. This study should enroll 
travellers during pre-travel consultations in the healthcare setting, as well as from external 
settings, such as airports or train stations, to capture travellers who may not have received 
illness-prevention education. Travellers should also represent a broad range of travel 
reasons, as well as travel to various destinations for assorted durations. A study with these 
attributes would limit biases and increase generalizability. We would like to use this 
opportunity to call for an international effort to collect the necessary data due to the paucity 
and limitations for such an important topic for the international travel community. 
Specifically, cohort studies would provide needed data to more precisely determine the rates 
of illness in international travellers.
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Table 2
Study characteristics used to determine the best estimate of the number of international travellers with a travel-
related illness (n = 9)
Study Data source Enrollment Data Collection Instrument(s) Timeframe(s)
Chen et al. Boston-Area Travel 
Medicine Network 
(BATMN)
Recruited at pre-travel 
consultation
Extraction from medical record
Weekly diary
Post-travel survey
At pre-travel visit
During travel
2–4 weeks post-travel
Vilkman et al. Travel clinic of 
Aava Medical 
Centre
Recruited at pre-travel 
consultation
Pre-travel questionnaire
Follow-up questionnaire
At pre-travel visit
3 weeks after pre-travel visit
Stoney et al. New Jersey 
Behavioural Risk 
Factor Survey 
(NJBRFS)
Random-digit-dialing NJBRFS Travel Health Module Travel in the previous 12 
months
Balaban et al. Large American 
public health 
agency
Recruited at pre-travel 
consultation
Pre-travel survey
Post-travel survey (web-based)
At pre-travel visit
N/A
Dia et al. Marseille Travel 
Medicine Centre
Recruited at pre-travel 
consultation
Pre-travel questionnaire
Post-travel questionnaire
At pre-travel visit
Within a week of return
Rack et al. Berlin Institute of 
Tropical Medicine
Recruited at pre-travel 
consultation
Extraction from medical record
Post-travel questionnaire
At pre-travel visit
N/A
Hill University of 
Connecticut Health 
Centre
Recruited at pre-travel 
consultation
Brief questionnaire (with possible 
telephone interview)
Standardized questionnaire (phone-
based)
Within 2 weeks after travel
2 months after travel
Steffen et al. N/A N/A Pre-travel questionnaire
Retrospective questionnaire
Just prior to boarding a 
flight
7 months after departure
Steffen Returning flights to 
Switzerland
Airplane Questionnaire Flight back to Switzerland
N/A, not available.
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Table 3
Illnesses acquired by international travellers in the included studies (n = 9)
Study (No. ill) Top 5 illnesses (%) No. (%) of travellers that sought medical care Hospitalizationsn
(%)
Chen et al.
(n = 400)
Diarrhoea (52)
Headache (26)
Fatigue (25)
Cough (24)
Runny/stuffy nose (24)
73 (18) 4 (<1)a
Vilkman et al.
(n = 363)b
Travellers’ diarrhoeac
Skin problem
Fever
Vomiting
Respiratory tract infection
N/A 3 (1)
Stoney et al.
(n = 48)
N/A N/A N/A
Balaban et al.
(n = 33)
Diarrhoea (21)
Sore throat (11)
Nausea/vomiting (9)
Congestion/runny nose (8)
Coughing (7)
6 (19) 1 (3)
Dia et al.
(n = 313)
Arthropod bite (62)
Diarrhoea (46)
Sunburn (36)
Vomiting (9)
Cough (8)
33 (11) 1 (<1)
Rack et al.
(n = 282)
Gastrointestinal (81)
Respiratory (32)
Fever (15)
Dermatologic (10)
44 (16) 1 (<1)
Hill
(n = 501)
Diarrhoea (46)
Respiratory tract symptoms (26)
Skin problem (8)
High altitude sickness (6)
Motion sickness (5)
59 (8) 2 (3)d
Steffen et al.
(n = 1209)
Severe diarrhoea (56)
Vomiting or abdominal cramps (26)
Common cold (14)
High fever over several days (13)
Dermatosis (8)
659 (55) 43 (1)
Steffen
(n = 7906) Diarrhoea
c
Constipation
Respiratory infections
Insomnia
Headache
N/A N/A
N/A, not available.
aOne traveller with heart disease and a pulmonary embolism; two others with unspecified chronic medical conditions; one unknown.
b
Based upon data available for 459 of the 460 ill travellers in this study.
c
Denominator could not be determined from the article.
dOne traveller with malaria and the other with angina..
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